Ironwood Pharmaceuticals Inc represents a strong dedication to improving the lives of patients through innovative medicines. Their corporate philosophy is centered around delivering breakthrough treatments and therapies that address unmet medical needs. With a focus on gastrointestinal diseases such as irritable bowel syndrome with constipation (IBS-C) and gastrointestinal (GI) disorders, Ironwood Pharmaceuticals aims to provide effective solutions for patients worldwide. Their commitment to scientific excellence, collaboration, and patient advocacy drives their pursuit of transformative healthcare solutions. Ironwood Pharmaceuticals Inc is committed to making a positive impact within the pharmaceutical industry by advancing patient care and wellbeing.

Ironwood Pharmaceuticals Inc is primarily present in the United States.

Ironwood Pharmaceuticals Inc has achieved significant milestones since its inception. Notably, the company successfully developed and gained regulatory approval for its flagship drug, LINZESS® (linaclotide), which is used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc also formed a strategic collaboration with Allergan plc (now part of AbbVie Inc) to co-develop and co-commercialize LINZESS®. Moreover, the company advanced its pipeline with the development of potential treatments for various gastrointestinal and renal disorders. Ironwood Pharmaceuticals Inc's commitment to innovation and its focus on improving patients' lives solidify its position as a leading pharmaceutical company in the market.

Ironwood Pharmaceuticals Inc is a leading biotechnology company specializing in the development and commercialization of innovative medicines. Founded in 1998, Ironwood has since focused on advancing treatments for gastrointestinal diseases and fibrotic conditions. With a strong dedication to research and development, the company has successfully brought several approved drugs to market. Ironwood Pharmaceuticals Inc has established itself as a key player in the pharmaceutical industry, continuously striving to improve patients' lives. Through its commitment to scientific excellence and breakthrough therapies, Ironwood Pharmaceuticals Inc has positioned itself as a trusted name in the healthcare sector.

The main competitors of Ironwood Pharmaceuticals Inc in the market include Allergan plc, AstraZeneca plc, Pfizer Inc, and Takeda Pharmaceutical Company Limited.

Ironwood Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Ironwood Pharmaceuticals Inc revolves around developing and commercializing innovative medicines for patients with gastrointestinal (GI) diseases. The company focuses on discovering, developing, and marketing medicines for indications like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc leverages its expertise in the GI field to identify and advance potential therapies that address significant unmet needs in patient care. By prioritizing research and development, the company aims to improve the lives of individuals suffering from GI disorders and enhance their overall quality of life.

Коефициентът на цена спрямо печалбата (КЦП) на Ironwood Pharmaceuticals е 11,93.

Коефициентът на цена към оборот (KUV) на Ironwood Pharmaceuticals е 2,31.

AlleAktien качественият резултат за Ironwood Pharmaceuticals е 4/10.

очаквана Ironwood Pharmaceuticals оборотът е 418,25 млн. USD.

очаквана Ironwood Pharmaceuticals печалба е 81,07 млн. USD.

Ironwood Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the research, development, and commercialization of innovative drugs for the treatment of serious diseases. The business model of Ironwood is based on the invention and commercialization of new drugs to improve the health and quality of life of patients. The company specializes in the development of therapeutics in the fields of gastroenterology, hepatology, oncology, and neuroscience. An important segment of Ironwood's business model is partnerships with other companies. Ironwood collaborates with numerous partners and hospitals to optimize the research and development of therapeutics. For example, Ironwood works with the Canadian company Allergan to market the gastrointestinal motility agent Linzess. Ironwood also has its own sales and marketing organization that focuses on promoting and marketing its products. The company aims to bring its products to the global market and maintain its leading position in the industry. One of Ironwood's leading products is Linzess, the first and only prescription medication for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. Linzess aims to alleviate the symptoms of these conditions by increasing intestinal motility and facilitating bowel movements. Another important product of Ironwood is Zurampic, a medication for the treatment of gout in adults in combination with a xanthine oxidase inhibitor. Zurampic helps reduce uric acid in the body by increasing its excretion through the kidneys. Ironwood also has products in the pipeline that are in different stages of clinical development. These include IW-3718 for the treatment of reflux diseases and Olinciguat for the treatment of cystic fibrosis-associated respiratory complications. Overall, Ironwood has successfully built a business model specializing in the discovery and development of new drugs, with a focus on gastroenterology, hepatology, oncology, and neuroscience. The company works closely with partners and hospitals to optimize the research and development of therapeutics and market its products worldwide. With leading products like Linzess and Zurampic, along with promising products in the pipeline, Ironwood remains an important player in the industry.

Ironwood Pharmaceuticals разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Ironwood Pharmaceuticals в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Ironwood Pharmaceuticals е US46333X1081.

WKN на Ironwood Pharmaceuticals е A0X789.

Тикерът на Ironwood Pharmaceuticals е IRWD.

През последните 12 месеца Ironwood Pharmaceuticals изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Ironwood Pharmaceuticals да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Ironwood Pharmaceuticals в момента е .

Ironwood Pharmaceuticals изплаща дивидент на тримесечие. Той се разпределя в месеците .

Ironwood Pharmaceuticals платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Ironwood Pharmaceuticals се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Ironwood Pharmaceuticals на 5.07.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 5.07.2024 г..

Последното дивидентно плащане беше извършено на 5.07.2024 г..

През година 2023 Ironwood Pharmaceuticals изплати 0 USD под формата на дивиденти.

Дивидентите от Ironwood Pharmaceuticals се изплащат в USD.